TD Cowen analyst Josh Jennings maintained a Buy rating on Cerus today and set a price target of $5.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Josh Jennings has given his Buy rating due to a combination of factors that highlight Cerus’s potential for growth and undervaluation. He notes that Cerus’s current stock price does not fully account for its growth opportunities, particularly with the IFC product, which has received positive feedback from users for its efficiency and cost-effectiveness. This feedback suggests a broader adoption trend that could significantly benefit the company.
Furthermore, Jennings points out that Cerus has a promising growth trajectory supported by an expanding product lineup and entry into new markets. Despite recent underperformance in the stock market, the company’s strategic goals for 2025 appear achievable, and its new product lines, like IFC, along with upcoming regulatory approvals, could enhance its valuation. The INTERCEPT Platelets franchise, while already capturing market share, still has significant room for growth, indicating further potential for revenue increase.
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CERS in relation to earlier this year.